Using AD rodent models, it was demonstrated that NSCs reduce tau and Aβ expression levels (Lee et al., 2015); promote neurogenesis and synapse formation (Ager et al., 2015; Lilja et al., 2015), reduce neuroinflammation (Zhang et al., 2016); and reverse cognitive deficits (Ager et al., 2015; Lilja et al., 2015; Zhang et al., 2016). The gene discussed is MAPT; the disease is Alzheimer disease.